How to Get Trulicity (Dulaglutide) in Mississippi

What Trulicity Is and Why Mississippi Patients Seek It

Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist that lowers blood glucose, reduces appetite, and, in patients with established cardiovascular disease or multiple risk factors, cuts the risk of heart attack, stroke, and cardiovascular death. The FDA first approved dulaglutide in 2014 for glycemic control in type 2 diabetes; the cardiovascular indication was added in 2020 based on the REWIND trial [1].

Mississippi carries one of the highest rates of type 2 diabetes in the United States. The CDC's 2023 surveillance data place Mississippi's diagnosed diabetes prevalence at roughly 14.5%, well above the national average of 11.6% [2]. That burden drives high demand for GLP-1 receptor agonists, including dulaglutide, across the state.

REWIND (N=9,901, median follow-up 5.4 years) demonstrated that dulaglutide 1.5 mg once weekly produced a statistically significant 12% relative risk reduction in the composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death compared to placebo (hazard ratio 0.88; 95% CI 0.79, 0.99; P=0.026) [1]. Participants in REWIND had a lower baseline cardiovascular event rate than those in most other GLP-1 cardiovascular outcomes trials, making the results especially applicable to the broad, primary-prevention-adjacent population often seen in Mississippi primary care.

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes who also have established atherosclerotic cardiovascular disease or who are at high cardiovascular risk [3]. Dulaglutide meets that criterion.

Step 1: Confirm You Qualify for a Trulicity Prescription

A prescriber in Mississippi will assess four core eligibility criteria before writing the prescription. Meeting all four makes prior authorization significantly easier and reduces the chance of a denial.

Diagnosis of type 2 diabetes. Trulicity is FDA-labeled for type 2 diabetes only. Accepted diagnostic criteria from the American Diabetes Association include a fasting plasma glucose of 126 mg/dL or higher on two separate occasions, a 2-hour plasma glucose of 200 mg/dL or higher during an oral glucose tolerance test, a hemoglobin A1c of 6.5% or higher, or a random glucose of 200 mg/dL or higher with classic hyperglycemia symptoms [3]. Your prescriber will want at least one of these documented in your chart before submitting any prior authorization.

No absolute contraindications. Dulaglutide carries a boxed warning for a risk of thyroid C-cell tumors observed in rodents; it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 [4]. Patients with severe gastroparesis or a known hypersensitivity to dulaglutide or any component of the formulation are also excluded [4].

Baseline labs completed. Most Mississippi prescribers and all insurance prior authorization workflows require recent lab work. The minimum set is: hemoglobin A1c, comprehensive metabolic panel (to assess renal function, as dulaglutide requires dose consideration in eGFR <15 mL/min/1.73m²), fasting lipid panel, and a urine albumin-to-creatinine ratio. Some payers also require documentation that metformin was tried first, unless metformin is contraindicated.

Not currently pregnant. Dulaglutide is Pregnancy Category not assigned (the old letter system was retired), but the FDA label states the drug may cause fetal harm and should be discontinued at least 2 months before a planned pregnancy [4]. Mississippi prescribers typically verify pregnancy status at the initial visit.

Step 2: Choose Your Prescriber Pathway in Mississippi

Mississippi offers three main pathways to a dulaglutide prescription. Each has different timelines and documentation requirements.

In-Person Visit with a Primary Care Physician or Endocrinologist

The most direct route is a scheduled appointment with a Mississippi-licensed MD or DO. Endocrinologists typically have the fastest prior authorization success rates because their specialty codes reduce payer scrutiny. Primary care physicians write the majority of Trulicity prescriptions in Mississippi, however, and most payers accept those without additional specialist documentation. Expect a 1 to 3 week wait for a new-patient appointment in urban areas (Jackson, Hattiesburg, Gulfport) and 4 to 8 weeks in rural counties.

Nurse Practitioner or Physician Assistant Visit

Mississippi amended its scope-of-practice regulations to allow nurse practitioners to practice with a collaborative agreement rather than direct supervision in many settings. PAs operate under a supervisory agreement with a licensed physician [5]. Both NPs and PAs may prescribe Schedule II-V controlled substances and non-controlled drugs, including dulaglutide. Federally Qualified Health Centers (FQHCs) across Mississippi often use NP-led care teams and can prescribe Trulicity with shorter wait times than private specialty practices.

Telehealth Prescribing in Mississippi

Mississippi permits telehealth prescribing for non-controlled substances after a valid prescriber-patient relationship is established via a synchronous audio-video encounter [6]. Dulaglutide is not a controlled substance, so it can be prescribed via telehealth in Mississippi provided the prescriber holds a current Mississippi medical or advanced practice license and the patient is physically located in Mississippi during the visit. Telehealth platforms that serve Mississippi residents can typically schedule an initial visit within 24 to 72 hours and transmit the prescription electronically to a retail or mail-order pharmacy the same day.

The HealthRX clinical team uses a four-question pre-visit intake to route Mississippi patients to the most appropriate prescriber pathway: (1) Has the patient had labs drawn within the past 90 days? (2) Does the patient have documented type 2 diabetes in a prior medical record? (3) Does the patient have any contraindications to GLP-1 therapy? (4) Does the patient carry commercial insurance, Medicaid, or Medicare? Patients who answer yes to the first two questions, no to the third, and who have commercial insurance are routed directly to telehealth to minimize time to prescription. Patients on Medicaid are counseled about the coverage gap before the visit to set expectations.

Step 3: Get Your Labs Drawn Before the Visit

Labs drawn before your telehealth or in-person appointment accelerate the prescription process. They let the prescriber make a clinical decision on the day of the visit rather than waiting for results. Mississippi has Quest Diagnostics and LabCorp draw sites in all major metropolitan areas, and many CVS MinuteClinics in the state offer basic metabolic panels [7].

The FDA label for dulaglutide specifies no required dose adjustment for mild-to-moderate renal impairment, but clinical experience and the 2024 ADA Standards of Care call for caution and monitoring when eGFR falls below 30 mL/min/1.73m² [3][4]. Getting a creatinine and eGFR documented before the visit prevents delays.

A hemoglobin A1c drawn within the past 90 days is accepted by most Mississippi commercial payers as the primary glycemic documentation for prior authorization. If yours is older than 90 days, order a new one before your appointment. The 2024 ADA recommends testing A1c at least twice per year in patients who are meeting treatment goals and quarterly in patients whose therapy has changed or who are not at goal [3].

Step 4: Understand Mississippi's Prior Authorization Requirements

Prior authorization (PA) is required for Trulicity by most commercial payers operating in Mississippi, including BlueCross BlueShield of Mississippi, Humana, Aetna, Cigna, and United Healthcare. Mississippi Medicaid does not cover Trulicity for type 2 diabetes as of 2025, so a PA submission to Mississippi Division of Medicaid will not succeed for this indication.

Standard PA documentation packages for Mississippi commercial plans include: a letter of medical necessity from the prescriber, a current A1c result, documentation that metformin was trialed at an adequate dose (typically 1 to 000 mg twice daily for at least 90 days) and either failed to achieve glycemic goals or was not tolerated, and evidence of a type 2 diabetes diagnosis with ICD-10 code E11.xx. Some plans additionally require documentation of a cardiovascular risk assessment if the prescriber is requesting the cardiovascular risk-reduction indication.

The 2022 American Diabetes Association consensus report on improving access to diabetes medications states that prior authorization processes "create barriers to timely medication access and may contribute to clinical inertia" [8]. Despite this, PA remains the standard payer mechanism in Mississippi for GLP-1 agents. Most commercial PA decisions are returned within 3, 5 business days. Urgent PA, available when clinical urgency is documented, can be resolved in 72 hours under Mississippi insurance law.

If a PA is denied, the prescriber can file a peer-to-peer review request or an appeal. First-level appeals that include updated clinical documentation have approval rates above 50% in most Mississippi commercial plans, based on published payer appeal data [9].

Step 5: Fill Your Prescription at a Mississippi Pharmacy or via Mail Order

Once the prescription is approved, Mississippi residents have several fill options.

Retail pharmacies. Walgreens, CVS, Walmart, and Kroger pharmacies across Mississippi stock Trulicity in the 0.75 mg and 1.5 mg single-dose pens. The 3 mg and 4.5 mg doses may require a 24-to-48-hour special order at smaller independent pharmacies in rural areas.

Mail-order and specialty pharmacies. Express Scripts, Optum Rx, and CVS Caremark all ship to Mississippi addresses. Mail-order typically provides a 90-day supply at a reduced per-dose cost compared to 30-day retail fills for patients with commercial insurance that includes a mail-order benefit.

503A compounding pharmacies. Licensed 503A compounding pharmacies in Mississippi may compound dulaglutide for patients with a valid patient-specific prescription from a licensed practitioner. The FDA does not approve compounded drugs the way it approves brand-name products, and compounded dulaglutide is not bioequivalent-tested against Trulicity [10]. Patients choosing this route should confirm that the compounding pharmacy holds a current Mississippi State Board of Pharmacy license and complies with USP <797> sterile compounding standards.

Lilly savings programs. Eli Lilly's Trulicity savings card program, available at LillyInsulin.com and through the Lilly Cares Foundation, can reduce monthly out-of-pocket cost to $25 for eligible commercially insured patients. Patients without insurance who meet income criteria may qualify for the Lilly Insulin Value Program or the Lilly Cares Patient Assistance Program, which provides Trulicity at no cost [11].

Dosing, Administration, and Titration in Mississippi Clinical Practice

Trulicity is available in four doses: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg, all administered once weekly via subcutaneous injection into the abdomen, thigh, or upper arm. The FDA label and the ADA 2024 Standards of Care recommend starting at 0.75 mg once weekly and titrating to 1.5 mg after 4 weeks if tolerated. Further titration to 3 mg and then 4.5 mg may occur at 4-week intervals based on glycemic response and tolerability [3][4].

The AWARD-11 trial (N=1,842) demonstrated that dulaglutide 3 mg and 4.5 mg produced significantly greater A1c reductions than 1.5 mg (mean A1c reduction of 1.9% and 2.1% vs. 1.5% at 36 weeks, respectively; P<0.001 for both comparisons) and greater weight reductions (4.7 kg and 4.9 kg vs. 3.0 kg) [12]. Mississippi clinicians managing patients who do not reach A1c goals on 1.5 mg should consider titration before switching agents.

The most common adverse effects are gastrointestinal: nausea (12 to 21% in clinical trials), diarrhea (8 to 12%), vomiting (6 to 9%), and decreased appetite [4]. These effects are typically dose-dependent and peak in the first 4 weeks, then diminish. Starting patients on 0.75 mg and advising them to eat smaller, lower-fat meals during the titration period reduces dropout due to GI intolerance.

Cardiovascular Evidence Supporting Use in High-Risk Mississippi Patients

Mississippi's cardiovascular disease mortality rate consistently ranks among the five highest in the nation [2]. The REWIND trial is directly relevant because it enrolled a broader population than most cardiovascular outcomes trials: only 31.5% of REWIND participants had prior cardiovascular events at baseline, compared to 83% in LEADER (liraglutide) and 100% in SUSTAIN-6 (semaglutide) [1][13][14].

The REWIND authors wrote, "Our results suggest that the cardiovascular benefit of dulaglutide may extend to patients with type 2 diabetes at lower levels of cardiovascular risk than those included in most previous cardiovascular outcomes trials" [1]. That framing makes dulaglutide a particularly relevant choice for Mississippi primary care practices managing patients with type 2 diabetes and two or more cardiovascular risk factors who have not yet had a clinical event.

A 2021 network meta-analysis published in The Lancet Diabetes and Endocrinology (covering 764 trials and 421,346 participants) found that GLP-1 receptor agonists as a class reduced all-cause mortality and cardiovascular mortality in people with type 2 diabetes, with dulaglutide among the agents with the most strong cardiovascular evidence [15].

Special Populations in Mississippi: Rural Access, Medicare, and Low-Income Patients

Rural access. Approximately 51% of Mississippi's population lives in rural counties with limited specialty care [2]. Telehealth prescribing closes this gap substantially. A rural Mississippi patient can complete an initial video visit from home, have labs drawn at a local hospital outpatient lab or critical access hospital, and receive Trulicity via mail-order within 5, 10 business days.

Medicare Part D. Most Medicare Part D plans cover Trulicity, though formulary tier placement varies. Many plans place dulaglutide on Tier 3 or Tier 4, resulting in significant cost-sharing. The Inflation Reduction Act caps out-of-pocket spending for Medicare Part D enrollees at $2,000 annually starting in 2025, which improves affordability for Mississippi Medicare beneficiaries who previously faced high spending in the catastrophic coverage phase [16].

Low-income uninsured patients. The Lilly Cares Foundation Patient Assistance Program provides Trulicity at no cost to qualifying patients who meet income thresholds (typically at or below 400% of the federal poverty level) and have no insurance coverage for the drug [11]. Mississippi community health centers and FQHCs often have patient assistance program navigators who can complete the enrollment paperwork on the patient's behalf.

Monitoring After Starting Trulicity in Mississippi

The ADA 2024 Standards of Care recommend measuring A1c every 3 months when initiating or adjusting therapy, then every 6 months once stable [3]. Mississippi prescribers should also monitor:

Renal function (creatinine and eGFR) annually or more frequently if baseline eGFR is <60 mL/min/1.73m². Dulaglutide has been associated with acute kidney injury, generally secondary to GI-related volume depletion [4]. Patients should be counseled to increase fluid intake and contact their prescriber if they experience persistent vomiting or diarrhea.

Amylase and lipase only if the patient develops symptoms consistent with pancreatitis (persistent severe abdominal pain radiating to the back). Routine asymptomatic monitoring of these enzymes is not recommended by the FDA label [4] or the ADA [3].

Heart rate. GLP-1 receptor agonists increase resting heart rate by a mean of 2, 4 beats per minute [4]. This is generally not clinically significant but warrants attention in patients with pre-existing tachycardia or a history of arrhythmia.

Blood pressure. REWIND showed a mean systolic blood pressure reduction of approximately 1.7 mmHg for dulaglutide vs. placebo at 1 year [1]. Mississippi clinicians managing patients on antihypertensives should be alert to the possibility of additive blood pressure lowering, especially with the higher doses.

Thyroid palpation at each visit and thyroid-stimulating hormone measurement if nodules are detected. The boxed warning for thyroid C-cell tumors means any new neck mass warrants immediate evaluation [4].

Transferring an Existing Trulicity Prescription to Mississippi

Patients moving to Mississippi with an active Trulicity prescription from another state can transfer it to a Mississippi pharmacy. A pharmacy transfer is straightforward if the prescription has remaining refills and the out-of-state prescriber has a valid DEA registration (though Trulicity is not a controlled substance, the DEA registration signals active licensure).

If the out-of-state prescriber is not licensed in Mississippi, the pharmacist legally cannot fill additional refills beyond the original fill in most circumstances. The patient should establish care with a Mississippi prescriber promptly. A telehealth provider can often see a new patient within 24 to 72 hours and issue a new Mississippi prescription, bridging the gap without interruption of therapy. Bring your most recent labs, your prescription bottle, and a summary of your diabetes management history to that appointment to minimize time to a new prescription.